Early market entry is often necessary to generate revenue and support the commercialisation of innovation. Jasdeep Singh, CEO of SingleTimeMicroneedles, explains how his company bridged the financing gap through navigating alternatives to traditional regulatory and go-to-market strategies.

Grant funding can be a catalyst for scientific and commercial progress. Adriann Sax, CEO & Co-Founder of Vetigenics, shares how strategic use of SBIR and foundation grants enabled the company to build a canine antibody platform, attract support from investors, and secure partners such as Merck Animal Health.

A well-timed bridge investment can mean the difference between stalling and scaling. Dr. Asel Sartbaeva, CEO and co-founder of EnsiliTech, reflects on how family office support provided crucial bridge, enabled better deal terms, and positioned the company to close an oversubscribed £4.5 million round.

Machine learning is reshaping discovery science in Human Health and Organicin Scientific is proving its potential in animal health too. Mat Mitchell, Co-Founder and CTO, shares how Organicin Scientific’s machine-learning platform automates candidate selection to identify, evaluate, and commercialise novel antimicrobials for safe and sustainable use across the industry.